Mycogen Corp. announced that it has received approval fromthe Environmental Protection Agency (EPA) to market itsgenetically engineered M-Peril bioinsecticide, which targets theEuropean corn borer.

M-Peril is the San Diego company's third EPA-approvedproduct that incorporates its CellCap encapsulation deliverysystem for genetically engineering the organism Pseudomonasfluorescens to contain Bacillus thuringiensis toxin. In 1991,Mycogen's MVP and M-Trak bioinsecticides became the firsttwo genetically engineered biopesticides to receive federalregulatory approval for commercial sale.

Mycogen (NASDAQ:MYCO) has about 16.8 million outstandingshares, fully diluted, and had $68 million in cash at year end,according to Mike Sund, the director of corporatecommunications. The company's stock closed unchanged Fridayat $14.50 a share.

(c) 1997 American Health Consultants. All rights reserved.

No Comments